Results 161 to 170 of about 5,706,617 (283)

New therapies, new challenges: Cystic lung disease after cancer immunotherapy. [PDF]

Respir Med Case Rep
Venkatesh A, Camacho D, Summer R, Dong M.   +3 more
europepmc   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Evolution of cystic lung disease in Birt-Hogg-Dubé syndrome: assessment of older patients. [PDF]

BMJ Open Respir Res
Tzilas V, Wang R, Wei W, Hu X, Ryu JH.
europepmc   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Pulmonary Sarcomatoid (Pleomorphic) Carcinoma Presenting As Secondary Spontaneous Pneumothorax in Diffuse Cystic Lung Disease: A Case Report. [PDF]

Cureus
Annan GK, Mills-Annoh A, Afrifa-Yamoah J, Ekakitie P, Berchie PO.   +4 more
europepmc   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

Multidisciplinary respiratory rehabilitation after spontaneous pneumothorax in cystic lung disease: a case report with literature review. [PDF]

Respir Med Case Rep
Shi J, Jiang R, Yang Z, Yang S, Hu X.
europepmc   +1 more source

Human Gallbladder Cancer Organoids

Cell Proliferation, EarlyView.
This guideline provides standardized requirements and quality control measures for human gallbladder cancer organoids, supporting their reliable application in research and precision medicine. It aims to promote methodological consistency, facilitate international collaboration, and accelerate translational research and clinical implementation.
Dongxi Xiang, Ting Gong, Yinjie Zhu, Bin Jia, Chen Zhang, Ning Tang, Weiping Wang, Yalong Wang, Laiping Zhong, Yanmei Zou, Jian Zhang, Zunqiang Zhou, Ligang Xing, Changchun Zhou, Dongyuan Zhu, Zengjun Liu, Gang Chen, Xiaoguang Wang, Zhan Wang, Aina He, Yonggang Wang, Zebing Liu, Jiabei Wang, Feng Xu, Ganglong Gao, Xiaonan Kang, Shuai Gong, Xianming Kong, Chunyan Dong, Aijin Ma, Gengming Niu, Guiying Wei, Hongling Zhao, Xiongxiong Lu, Jie Cao, Tongbiao Zhao, Zizhen Zhang, Yingbin Liu   +37 more
wiley   +1 more source

A twin with a novel pathogenic variant in CYBB induced X-linked chronic granulomatous disease: a rare case report of misdiagnosis as congenital cystic lung disease. [PDF]

BMC Pediatr
Lin L, Gong Z, Yin G, Lu G, Peng J.
europepmc   +1 more source

Cystic Fibrosis and Colorectal Cancer Risk: Reprogramming of the Intestinal Epithelial Niche and Cell‐State Plasticity in the CFTR Modulator Era

Cell Proliferation, EarlyView.
In cystic fibrosis disorder, CFTR dysfunction drives multilayered intestinal niche disruption, including dysbiosis, inflammation, hypoxia, metabolic stress and genotoxic injury, promoting cell‐state plasticity and a pre‐neoplastic ecosystem. CFTR modulators and environmental factors may partially reshape these processes, highlighting opportunities for ...
Bala Umashankar, Ines Pankonien, Margarida Amaral, Chee Y. Ooi, Thierry Jardé, Shafagh A. Waters   +5 more
wiley   +1 more source